Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia

Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nix, Nancy M., Price, Allyson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521119/
https://www.ncbi.nlm.nih.gov/pubmed/33537166
http://dx.doi.org/10.6004/jadpro.2019.10.8.13
_version_ 1783587913307521024
author Nix, Nancy M.
Price, Allyson
author_facet Nix, Nancy M.
Price, Allyson
author_sort Nix, Nancy M.
collection PubMed
description Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews the mechanisms of action, indications, and clinical trial details for eight novel agents, as well as the current discussions surrounding monitoring minimal residual disease.
format Online
Article
Text
id pubmed-7521119
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-75211192021-02-02 Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia Nix, Nancy M. Price, Allyson J Adv Pract Oncol Review Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews the mechanisms of action, indications, and clinical trial details for eight novel agents, as well as the current discussions surrounding monitoring minimal residual disease. Harborside Press LLC 2019 2019-11-01 /pmc/articles/PMC7521119/ /pubmed/33537166 http://dx.doi.org/10.6004/jadpro.2019.10.8.13 Text en © 2019 Harborside™ http://creativecommons.org/licenses/by-nc-nd/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Nix, Nancy M.
Price, Allyson
Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
title Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
title_full Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
title_fullStr Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
title_full_unstemmed Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
title_short Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
title_sort optimizing use of newly approved agents for acute myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521119/
https://www.ncbi.nlm.nih.gov/pubmed/33537166
http://dx.doi.org/10.6004/jadpro.2019.10.8.13
work_keys_str_mv AT nixnancym optimizinguseofnewlyapprovedagentsforacutemyeloidleukemia
AT priceallyson optimizinguseofnewlyapprovedagentsforacutemyeloidleukemia

Ejemplares similares